Zobrazeno 1 - 10
of 52
pro vyhledávání: '"Shobha Dhadda"'
Autor:
Lawrence S. Honig, Marwan N. Sabbagh, Christopher H. van Dyck, Reisa A. Sperling, Steven Hersch, Andre Matta, Luigi Giorgi, Michelle Gee, Michio Kanekiyo, David Li, Derk Purcell, Shobha Dhadda, Michael Irizarry, Lynn Kramer
Publikováno v:
Alzheimer’s Research & Therapy, Vol 16, Iss 1, Pp 1-4 (2024)
Externí odkaz:
https://doaj.org/article/235d44fcb4a64fba89f8c186629bc9ac
Autor:
Lawrence S. Honig, Marwan N. Sabbagh, Christopher H. van Dyck, Reisa A. Sperling, Steven Hersch, Andre Matta, Luigi Giorgi, Michelle Gee, Michio Kanekiyo, David Li, Derk Purcell, Shobha Dhadda, Michael Irizarry, Lynn Kramer
Publikováno v:
Alzheimer’s Research & Therapy, Vol 16, Iss 1, Pp 1-12 (2024)
Abstract Background Alzheimer disease (AD) is a major health problem of aging, with tremendous burden on healthcare systems, patients, and families globally. Lecanemab, an FDA-approved amyloid beta (Aβ)-directed antibody indicated for the treatment
Externí odkaz:
https://doaj.org/article/37323811cfca4e539a625fdbaee2b067
Autor:
Viswanath Devanarayan, Daniel A. Llano, Yan Helen Hu, Harald Hampel, Lynn Kramer, Shobha Dhadda, Michael Irizarry
Publikováno v:
Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring, Vol 16, Iss 3, Pp n/a-n/a (2024)
Abstract Plasma pTau181, a marker of amyloid and tau burden, was evaluated as a prognostic predictor of clinical decline and Alzheimer's disease (AD) progression of amyloid‐positive (Aβ+) patients with mild cognitive impairment (MCI). The training
Externí odkaz:
https://doaj.org/article/213befed8ac54b48976227fe3b8e2375
Autor:
Kathleen A. Welsh‐Bohmer, Geoffrey A. Kerchner, Shobha Dhadda, Miguel Garcia, David S. Miller, Fanni Natanegara, Lars Lau Raket, Weining Robieson, Eric R. Siemers, Maria C. Carrillo, Christopher J. Weber
Publikováno v:
Alzheimer’s & Dementia: Translational Research & Clinical Interventions, Vol 9, Iss 4, Pp n/a-n/a (2023)
Abstract The efficient and accurate execution of clinical trials testing novel treatments for Alzheimer's disease (AD) is a critical component of the field's collective efforts to develop effective disease‐modifying treatments for AD. The lengthy a
Externí odkaz:
https://doaj.org/article/b8fe5eb288c64421be7d95e7fa3df0d5
Autor:
Eric McDade, Jeffrey L. Cummings, Shobha Dhadda, Chad J. Swanson, Larisa Reyderman, Michio Kanekiyo, Akihiko Koyama, Michael Irizarry, Lynn D. Kramer, Randall J. Bateman
Publikováno v:
Alzheimer’s Research & Therapy, Vol 14, Iss 1, Pp 1-17 (2022)
Abstract Background Lecanemab, a humanized IgG1 monoclonal antibody that targets soluble aggregated Aβ species (protofibrils), has demonstrated robust brain fibrillar amyloid reduction and slowing of clinical decline in early AD. The objective of th
Externí odkaz:
https://doaj.org/article/a6d9281674a5413f8b67e7a74816d854
Autor:
Shobha Dhadda, Michio Kanekiyo, David Li, Chad J. Swanson, Michael Irizarry, Scott Berry, Lynn D. Kramer, Donald A. Berry
Publikováno v:
Alzheimer’s Research & Therapy, Vol 14, Iss 1, Pp 1-9 (2022)
Abstract Background Lecanemab (BAN2401) is a humanized IgG1 monoclonal antibody that preferentially targets soluble aggregated Aβ species (protofibrils) with activity at insoluble fibrils and slowed clinical decline in an 18-month phase 2 proof-of-c
Externí odkaz:
https://doaj.org/article/4ce48fe8ab7742dd95eb4cc183c3ed7b
Autor:
Kazuto Yamashita, Masahiro Miura, Shunsuke Watanabe, Kengo Ishiki, Yuji Arimatsu, Junko Kawahira, Toshiko Kubo, Katsutaka Sasaki, Takayuki Arai, Kei Hagino, Yasuhiro Irino, Kota Nagai, David Verbel, Akihiko Koyama, Shobha Dhadda, Hayato Niiro, Shigeki Iwanaga, Toshiyuki Sato, Tomokazu Yoshida, Atsushi Iwata
Publikováno v:
Alzheimer’s Research & Therapy, Vol 14, Iss 1, Pp 1-10 (2022)
Abstract Background Clinicians, researchers, and patients alike would greatly benefit from more accessible and inexpensive biomarkers for neural β-amyloid (Aβ). We aimed to assess the performance of fully automated plasma Aβ immunoassays, which co
Externí odkaz:
https://doaj.org/article/b4ad83da56d5456eaf4df2dc531245d7
Autor:
Lawrence S. Honig, Jerome Barakos, Shobha Dhadda, Michio Kanekiyo, Larisa Reyderman, Michael Irizarry, Lynn D. Kramer, Chad J. Swanson, Marwan Sabbagh
Publikováno v:
Alzheimer’s & Dementia: Translational Research & Clinical Interventions, Vol 9, Iss 1, Pp n/a-n/a (2023)
Abstract INTRODUCTION Lecanemab is a humanized immunoglobulin G1 (IgG1) monoclonal antibody that preferentially targets soluble aggregated Aβ species (protofibrils) with activity at amyloid plaques. Amyloid‐related imaging abnormalities (ARIA) pro
Externí odkaz:
https://doaj.org/article/3cf542a8e09a48118eb52ac3667c50a8
Autor:
Chad J. Swanson, Yong Zhang, Shobha Dhadda, Jinping Wang, June Kaplow, Robert Y. K. Lai, Lars Lannfelt, Heather Bradley, Martin Rabe, Akihiko Koyama, Larisa Reyderman, Donald A. Berry, Scott Berry, Robert Gordon, Lynn D. Kramer, Jeffrey L. Cummings
Publikováno v:
Alzheimer’s Research & Therapy, Vol 13, Iss 1, Pp 1-14 (2021)
Abstract Background Lecanemab (BAN2401), an IgG1 monoclonal antibody, preferentially targets soluble aggregated amyloid beta (Aβ), with activity across oligomers, protofibrils, and insoluble fibrils. BAN2401-G000-201, a randomized double-blind clini
Externí odkaz:
https://doaj.org/article/edd30e11757844c3a76924e96d5411df
Autor:
Chad J. Swanson, Yong Zhang, Shobha Dhadda, Jinping Wang, June Kaplow, Robert Y. K. Lai, Lars Lannfelt, Heather Bradley, Martin Rabe, Akihiko Koyama, Larisa Reyderman, Donald A. Berry, Scott Berry, Robert Gordon, Lynn D. Kramer, Jeffrey L. Cummings
Publikováno v:
Alzheimer’s Research & Therapy, Vol 14, Iss 1, Pp 1-1 (2022)
Externí odkaz:
https://doaj.org/article/9e3c60d518ed4e89a11178d614b7e937